--- title: The MedTech Startup Ecosystem in Europe 2026 description: MedTech startup ecosystem Europe 2026: where the clusters are, how to read accelerators and public funding, and what to look for before joining a hub. authors: Tibor Zechmeister, Felix Lenhard category: MedTech Startup Strategy & PMF primary_keyword: MedTech startup ecosystem Europe 2026 canonical_url: https://zechmeister-solutions.com/en/blog/medtech-ecosystem-europe-2026 source: zechmeister-solutions.com license: All rights reserved. Content may be cited with attribution and a link to the canonical URL. --- # The MedTech Startup Ecosystem in Europe 2026 *By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.* > **The European MedTech startup ecosystem in 2026 is denser and more mature than it was five years ago, but it is also more uneven. Capital, clinical access, manufacturing capacity and regulatory expertise are not distributed equally across the continent. Choosing where to base, where to accelerate and where to pilot is a strategic decision, not a lifestyle one.** **By Tibor Zechmeister and Felix Lenhard.** ## TL;DR - European MedTech concentrates around half a dozen metro regions with distinct specialisations, not in a single capital. - Accelerators fall into four functional categories: generalist, clinical-access, deep-tech-hardware and regulatory-embedded. Choose the category that matches your current bottleneck. - Public-funded clusters and competence centres often provide better value than private accelerators for MDR-regulated startups, because they bundle lab access with non-dilutive funding. - Hub membership is useful, hub dependency is dangerous. Your regulatory roadmap cannot live inside someone else's programme calendar. - In 2026 the ecosystem advantage is no longer just capital. It is the combination of clinical partners, notified body proximity and a regulatory affairs talent pool. ## Why this matters Founders often ask Felix where they should base their company. The honest answer is: it depends on your device, your customers and what you are missing most right now. But there is a pattern underneath that answer, and the pattern is worth making explicit, because moving a company once it has employees and a QMS is painful. The European ecosystem is not Silicon Valley and never will be. It is a network of specialised clusters with different strengths. Munich is not Eindhoven. Vienna is not Cambridge. Treating "Europe" as one market when you choose a base is the same mistake as treating "Europe" as one market when you launch. It sounds strategic and it is actually sloppy. ## What MDR actually says MDR does not say anything about ecosystems. But two articles quietly shape where you should base. **Article 10** lays out general obligations of manufacturers, including the quality management system, technical documentation, clinical evaluation, post-market surveillance and the presence of a person responsible for regulatory compliance. Every one of these obligations is easier to fulfil in a region with deep regulatory talent and existing MedTech infrastructure, because you can hire and buy services locally instead of importing them at a premium. **Article 15** introduces the Person Responsible for Regulatory Compliance (PRRC). Micro and small enterprises do not need a PRRC in-house but must have one permanently and continuously at their disposal. In practice, finding a qualified PRRC in a region without MedTech density is hard. Ecosystem choice is quietly PRRC availability in disguise. Everything else. Accelerators, clusters, VC, clinical partners. Is commentary on how easily you can discharge your obligations under Article 10 and your access-to-PRRC obligation under Article 15. ## A worked example A founder approached Felix in 2024 with an AI imaging triage tool for emergency radiology. She had a strong clinical co-founder in Graz, a technical team remote across three countries and EUR 600k in seed money. Where should she base? Felix ran through four questions with her. **What is the biggest missing resource right now?** Clinical validation partners. The algorithm worked in retrospective data but had never run in a live ED. That pointed toward a region with strong university hospitals willing to run prospective pilots. Which in her case meant staying in the German-speaking space where her clinical co-founder had relationships. **What is the biggest missing resource in 12 months?** Regulatory affairs depth. She needed someone who had written CERs for AI devices under MDR. That talent is concentrated in a handful of regions. Austria, southern Germany and the Netherlands were at the top of the list. **What is the biggest missing resource in 24 months?** Growth capital. Series A for European MedTech AI is painful and regional. Having a notified body relationship already active and credible clinical data would matter more than postcode, but postcode still helps at Series A because pattern-matching VCs cluster. **Where is your notified body most likely to be?** For software-heavy AI devices, the pool of notified bodies with meaningful AI review capacity is small. Proximity to one of them reduces friction across every audit cycle. This is underrated. She stayed in Graz, joined an Austrian public-funded cluster programme for non-dilutive funding, partnered with two university hospitals for prospective data and hired her first regulatory affairs person from the local talent pool. Two years later her CER is defensible and her Series A conversations are open. The decision to stay was not obvious in the room but in retrospect it was the right one because it solved the bottleneck that was actually binding. ## The Subtract to Ship playbook Here is how to navigate the European MedTech ecosystem without getting lost in it. **Step 1. Map the clusters by function, not by fame.** Europe has recognisable MedTech density in several regions. Munich and Stuttgart for deep-tech hardware and large incumbents. Vienna and Graz for regulatory expertise, software devices and a dense notified body presence. Eindhoven for imaging, photonics and industrial MedTech spin-outs. Cambridge and Oxford for life sciences bridging into MedTech. Paris and Lyon for clinical research density. Leuven for academic spin-outs around imec. Copenhagen and Stockholm for digital health. Basel and Zurich for medtech–pharma crossovers. These are shorthand clusters, not exclusive territories. Each has a specialisation, and your device should match it. Specific programmes and organisations within each region change year to year. Verify any organisation-level recommendation before committing to it . **Step 2. Identify your current bottleneck.** Before you look at accelerators, name the one resource you are most missing. Capital, clinical access, engineering hires, regulatory expertise, manufacturing partners, or market access. Write it down. Then filter programmes by which bottleneck they actually unblock. Most accelerators claim to unblock everything and unblock one thing well. The gap between the pitch and the reality is where founders waste months. **Step 3. Classify accelerators by function.** There are four useful functional categories. Generalist accelerators (broad-stage, cohort-based, equity for programme). Clinical-access accelerators (partnered with university hospitals, offering validation-site access). Deep-tech-hardware accelerators (labs, workshops, prototyping capacity). Regulatory-embedded accelerators (MDR-aware programmes that offer QMS setup, NB introductions, PRRC support). The category matters more than the brand. A generalist accelerator cannot solve a clinical-access problem no matter how famous it is. **Step 4. Prefer public-funded clusters for MDR-regulated work.** Private accelerators trade equity for network and mentorship. Public-funded clusters typically trade application effort for non-dilutive grants, lab access and shared infrastructure. For MDR-regulated startups, the public-funded option is often materially better because the grants stretch runway through the long pre-revenue period that MDR imposes. See our posts on EU funding and Austrian funding for the mechanics. Specific funding programme details change annually. Verify current terms before applying . **Step 5. Use ecosystem membership, do not depend on it.** Accelerators run on their schedule. Your regulatory roadmap runs on yours. If your NB submission date is driven by a demo day, something is wrong. Join the programme, use the resources, keep your regulatory timeline sovereign. **Step 6. Evaluate clusters by three specific signals.** First, does the cluster have a notified body with relevant scope physically nearby or embedded? Second, does the cluster have at least one clinical partner willing to host a prospective pilot? Third, does the cluster have a local pool of qualified PRRCs and regulatory affairs professionals? If the answer to any of these is no, the cluster is pretty scenery, not infrastructure. **Step 7. Do not overvalue demo days and undervalue lab access.** Demo days produce logos on slides. Lab access produces test reports you actually need for your technical documentation. When in doubt, pick the boring resource. **Step 8. Plan your geography around PRRC availability.** Per Article 15, you need continuous access to a qualified PRRC. In regions with thin MedTech talent, the PRRC becomes a single point of failure. Base near the talent, or budget for remote PRRC arrangements early and document them in your QMS. A note on what this post deliberately avoids. Tibor and Felix are not naming specific accelerators, clusters or venture capital firms here. Programmes change scope, leadership and quality year to year, and a recommendation published in 2026 could mislead a founder in 2027. What does not change is the shape of the ecosystem, the functional categories and the questions to ask before joining anything. Current, verified organisation-level recommendations belong in a conversation, not in an evergreen post. ## Reality Check 1. Can you name your single biggest missing resource right now, in one word? 2. Does the programme or cluster you are evaluating actually unblock that resource, or does it unblock something adjacent? 3. Is there a notified body with relevant scope physically nearby? 4. Is there a clinical partner in the region willing to host a prospective pilot? 5. Can you hire a qualified PRRC locally, or will you need to import that expertise? 6. If you joined this programme, could you keep your regulatory timeline sovereign from the programme calendar? 7. Is the ecosystem choice you are considering a capital decision, a talent decision or an emotional decision? 8. In 24 months when you need Series A, will the postcode you chose help or hurt? ## Frequently Asked Questions **Is there one obvious place to base a MedTech startup in Europe?** No. The right answer depends on your device, your clinical needs and your team. Each of the major clusters has a specialisation, and mismatch costs more than geography. **Should I join a general accelerator or a MedTech-specific one?** If your bottleneck is generic (capital, team formation, early product), a generalist may work. If your bottleneck is regulatory, clinical or manufacturing, you need a MedTech-specific programme. Generalists typically cannot unblock those. **Are European accelerators worth the equity they take?** Sometimes. Model the trade honestly. If you give up 6 to 8 percent of your company, the programme must deliver more than that in capital, network or validation. For MDR-regulated startups, public-funded clusters often beat equity-taking accelerators on pure math. **What about EIC Accelerator and other EU-level programmes?** These are valuable, distinct and worth a separate post. See our post on EIC Accelerator for the mechanics of the application. **How do I evaluate a cluster from outside?** Ask for three references from founders who finished their programme and are still in business. Ask those founders one question: which single resource did the cluster unblock for you? If you cannot get a specific answer, the cluster is not actually unblocking anything specific. **Do I need to be in Europe to CE mark?** No. But you need an authorised representative in the EU per MDR. Being based inside the EU removes an entire category of friction from your day-to-day regulatory work. ## Related reading - [EU Funding for MedTech Startups](/blog/eu-funding-medtech-startups) – how to use non-dilutive EU programmes. - [Austrian Funding for MedTech Startups](/blog/austrian-funding-medtech-startups) – a regional playbook inside the cluster. - [Venture Capital for MedTech in Europe 2026](/blog/venture-capital-medtech-europe-2026) – where the Series A money actually sits. - [EIC Accelerator for MedTech](/blog/eic-accelerator-medtech-application) – the flagship EU programme unpacked. - [MedTech Startup Team: Key Roles](/blog/medtech-startup-team-key-roles) – the people your ecosystem needs to supply. ## Sources 1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 10 and 15. 2. EN ISO 13485:2016+A11:2021. QMS requirements underpinning ecosystem infrastructure needs. --- *This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*